Phase 2a Study of HIV-1 Investigational Maturation Inhibitor
Demonstration of positive results for therapy designed to attack virus in a new way
27-Oct-2015 -
Bristol-Myers Squibb Company announced overall antiviral activity and safety results from the three-part Phase 2a proof-of-concept study of BMS-955176, a novel investigational therapy designed to prevent the maturation of HIV-1.The study findings support the continued development of BMS-955176, ...
AIDS
Bristol-Myers Squibb
clinical trials
+2